

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/138202>

Please be advised that this information was generated on 2021-04-17 and may be subject to change.

IMPG2-Associated Retinitis Pigmentosa Displays Relatively Early Macular Involvement

Ramon A. C. van Huet,¹ Rob W. J. Collin,^{2,3} Anna M. Siemiatkowska,^{2,3} Caroline C. W. Klaver,⁴ Carel B. Hoyng,¹ Francesca Simonelli,⁵ Muhammad I. Khan,^{2,6} Raheel Qamar,^{6,7} Eyal Banin,⁸ Frans P. M. Cremers,^{2,3} Thomas Theelen,¹ Anneke I. den Hollander,¹ L. Ingeborgh van den Born,⁹ and B. Jeroen Klevering¹

¹Department of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands

²Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands

³Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

⁴Erasmus University Rotterdam Medical Center, Rotterdam, The Netherlands

⁵Department of Ophthalmology, Seconda Università degli Studi di Napoli, Naples, Italy

⁶Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan

⁷Shifa College of Medicine, Islamabad, Pakistan

⁸Department of Ophthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

⁹The Rotterdam Eye Hospital, Rotterdam, The Netherlands

Correspondence: B. Jeroen Klevering, Department of Ophthalmology, Radboud University Medical Center, Philips van Leydenlaan 15, 6525 EX, Nijmegen, The Netherlands; Jeroen.Klevering@Radboudumc.nl

Submitted: February 10, 2014

Accepted: May 19, 2014

Citation: van Huet RAC, Collin RWJ, Siemiatkowska AM, et al. IMPG2-associated retinitis pigmentosa displays relatively early macular involvement. *Invest Ophthalmol Vis Sci*. 2014;55:3939-3953. DOI:10.1167/iov.14-14129

PURPOSE. To provide the first detailed clinical description in patients with RP caused by recessive mutations in *IMPG2*.

METHODS. This international collaborative study includes 17 RP patients with inherited retinal disease caused by mutations in *IMPG2*. The patients were clinically (re-)examined, including extensive medical history taking, slit-lamp biomicroscopy, ophthalmoscopy, perimetry, ERG, optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, fundus photography, and color vision tests. The main outcome measures included mean age at onset, initial symptom, best-corrected visual acuity, fundus appearance, perimetry results, ERG responses, OCT images, FAF imaging, color vision test reports and DNA sequence variants.

RESULTS. The mean age at onset was 10.5 years (range, 4–20 years). Initial symptoms included night blindness in 59% of patients, a decreased visual acuity in 35%, and visual field loss in 6%. Fundus abnormalities were typical of RP: optic disc pallor, attenuated vessels, bone spicules, and generalized atrophy of the retina and choriocapillaris. Additionally, we observed macular abnormalities in all patients, ranging from subtle mottling of the macular pigment epithelium (two patients) and a bull's eye maculopathy (seven patients) to macular chorioretinal atrophy (seven patients).

CONCLUSIONS. Mutations in *IMPG2* cause a severe form of RP with symptoms manifesting in the first 2 decades of life. *IMPG2*-associated RP is frequently accompanied by macular involvement, ranging from mild pigment alterations to profound chorioretinal atrophy. The resulting decrease in central vision in combination with the severe tunnel vision leads to severe visual impairment in patients with *IMPG2*-associated RP.

Keywords: Retinitis pigmentosa, IMPG2, macular atrophy, bull's eye maculopathy, natural course.

Retinitis pigmentosa (RP) is a group of diseases featuring progressive degeneration of rod and cone photoreceptor cells and RPE, and is considered the most commonly inherited retinal dystrophy with an estimated prevalence of approximately 1:4000.^{1–3} Retinitis pigmentosa typically starts with night blindness followed by loss of the peripheral visual field that leads to tunnel vision, whereas visual acuity often remains normal until the late stages.^{3,4} Hallmark fundus abnormalities in RP are bone-spicule pigmentation, a waxy pale optic disc, and attenuation of retinal vessels. Electroretinography (ERG) responses reveal rod and cone dysfunction, where rod abnormalities often are observed earlier in the course of the disease. However, wide variability in terms of disease onset,

progression rate, and degeneration patterns are observed in RP.^{4,5}

The genetic background underlying RP is also very heterogeneous. Inheritance modes observed in RP include autosomal-recessive (30% of patients), autosomal-dominant (20%), X-linked (10%), mitochondrial (<1%) patterns, and a few cases of digenic RP.^{6–9} However, the remaining 40% of patients are isolated cases.¹⁰ Autosomal recessive RP is currently associated with mutations in 42 different genes (RetNet, available in the public domain at <https://sph.uth.edu/retnet/>), which provide a molecular genetic explanation for approximately 50% of all recessive RP cases.¹¹ The proteins encoded by these genes are involved in a broad range of cellular

functions, including phototransduction, the visual (retinoid) cycle, transport along the connecting cilium, cell-to-cell signaling or synaptic interaction, gene regulation, cell or cytoskeletal structure, cell-cell interactions, and outer segment phagocytosis.^{4,10,12}

Recently, mutations in the *IMPG2* gene have been implicated in autosomal recessive RP.¹³ This gene encodes the interphotoreceptor matrix proteoglycan-2 (*IMPG2*), formerly known as IPM 200 or SPACRCAN,¹⁴ which is localized in the retinal extracellular matrix (also known as the interphotoreceptor matrix [IPM]). The IPM is a viscous substance mainly composed of glycoproteins and proteoglycans that fills the space between individual photoreceptor cells and between photoreceptors and the RPE.^{15,16} For many years, the IPM was considered merely a fixating medium,¹⁷ but in the past few decades multiple functions of the IPM have been reported, including important functions in intercellular communication, regulation of neovascularization, cell survival, membrane turnover, photoreceptor differentiation and maintenance, retinoid transport, matrix turnover, and the precise alignment of the photoreceptor cells to the optical light path.^{14,18,19} Both rod and cone photoreceptor cells synthesize *IMPG2* and secrete the protein into the IPM,²⁰ where it binds to other proteins, such as hyaluronan, and also seems to be anchored in the plasma membrane of the photoreceptor cells, thereby fixating the photoreceptors in the IPM.²¹ Additionally, *IMPG2* is thought to have calcium-binding potential, which suggests it has an important role in sequestering extracellular calcium released by photoreceptors in response to light.²¹

Knowledge of the natural course of *IMPG2*-related RP is of significant importance for prognosis counseling as well as genetic counseling. Furthermore, this knowledge is vital in the view of emerging therapy trials, in terms of patient selection and the assessment of treatment effects. In this international collaborative study, we aim to provide a detailed overview of the clinical findings in patients with *IMPG2*-associated RP.

METHODS AND PATIENTS

Subjects and Genetic Analysis

The specialized ophthalmogenetic centers of the Radboud University Medical Center (RACvH, CBH, and BJK), the Rotterdam Eye Hospital (LIVdB), the Erasmus University Medical Center Rotterdam (CCWK), the Hadassah-Hebrew University Medical Center in Jerusalem (EB), the Seconda Università degli Studi di Napoli (FS), and the Shifa College of Medicine in Islamabad (RQ) participated in this study. As described previously,¹³ six families of Israeli, Palestinian, Pakistani, Italian, or Dutch origin were found to carry causative mutations in *IMPG2* (families A-F, Fig. 1). Additionally, we selected four more families after identification of causative *IMPG2* mutations in a targeted next-generation sequencing experiment in 100 Dutch RP probands (family G),²² or whole exome sequencing (families H, J, K, Fig. 1). Exome sequencing was performed using the 5500xl Genetic Analyzer of Life Technologies (Applied Biosystems, Foster City, CA, USA) and the Agilent SureSelectXT Human All Exon 50-Mb amplification kit (Agilent Technologies, Inc., Santa Clara, CA, USA). Data were analyzed with LifeScope software (version 2.1; Life Technologies, Applied Biosystems). All mutations were confirmed with Sanger sequencing.

We adhered to the tenets of the Declaration of Helsinki and obtained approval for this study from the Institutional Ethics Committee from the Radboud University Medical Center. Approval included permission to use the documented medical

data and, when indicated, clinically reassess affected individuals and to obtain blood for the purposes of DNA extraction and genetic analysis. We obtained informed consent from all participants before the collection of blood samples and additional ophthalmologic examinations.

Clinical Analysis

We collected the available clinical data from the medical files of all patients. Nine patients were clinically reevaluated after the identification of causative *IMPG2* mutations. Medical history was registered with a focus on the age at onset, initial symptoms, and the overall course of the retinal disorder. The age at onset was defined as the age at which the initial symptom was noticed by the patient. Additionally, we questioned patients about the presence of syndromic features, which generally occur in 20% to 30% of RP patients.⁴ This questionnaire included the presence of hearing and balance abnormalities, renal failure, cardiac and respiratory anomalies, polydactyly, obesity, cognitive impairment, fertility disorders, hypogonadism, and dental anomalies.

Clinical examination included best-corrected visual acuity (BCVA), slit-lamp biomicroscopy, and ophthalmoscopy. Additional examinations were performed if feasible. Goldmann (kinetic) perimetry was performed in 11 patients using targets V-4e, III-4e, I-4e, I-3e, I-2e, and I-1e. In two patients (F-II:1 and F-II:2) perimetry was restricted to analysis of the central 30° of the visual field with the Humphrey perimeter (Carl Zeiss Meditec, Jena, Germany). In all but one patient (F-II:2), full-field ERG was performed according to the guidelines of the International Society for Clinical Electrophysiology of Vision.²³ Results were compared to the local reference values. We evaluated color vision in six patients using the Farnsworth Dichotomous Test (Panel D-15) and/or the Hardy-Rand-Rittler test. Fundus photographs of the central retina (Topcon TRC50IX; Topcon Corporation, Tokyo, Japan) were obtained in 15 patients. Fundus autofluorescence images (Spectralis; Heidelberg Engineering, Heidelberg, Germany) of the central retina were acquired in eight patients using a confocal scanning laser ophthalmoscope with an optically pumped solid state laser (488 nm) for excitation. Spectral-domain optical coherence tomography (SD-OCT, Spectralis; Heidelberg Engineering) could be performed in 13 patients. In three patients, a high-resolution OCT was not available and a time-domain OCT (Stratus; Carl Zeiss Meditec) was obtained. No OCT images were available for the remaining four patients. In eight Dutch patients with high-resolution SD-OCT images (mean age: 51 years; range, 23–67 years), we quantified thickness of the total retina at the foveola and at 0.25, 0.5, 1.0, 1.5, 2.0, and 2.5 mm eccentricity from the foveola in the right eye using the thickness graphs in the Heidelberg Eye Explorer Software (version 1.6.4.0; Heidelberg Engineering). In seven of these patients, we quantified the foveal volume by measuring the retinal volume within the central 3 mm² using the thickness map in the Heidelberg Eye Explorer Software (version 1.6.4.0; Heidelberg Engineering). A normal dataset of retinal thickness and foveal volume in individuals without (vitreo)retinal disease was obtained from 25 age-matched Dutch individuals (mean age: 46 years; range, 27–62 years) for reference purposes.

RESULTS

Ten families with a total of 17 affected individuals were included in this study. The pedigrees of all families are depicted in Figure 1. An overview of the clinical findings in all 17 patients is provided in Table 1.




FIGURE 1. Pedigrees of the families that were included in this study. Where relatives were available (families A, B, C, F, G, and H), the mutation segregates with the disease. Plus signs denote the wild-type allele, square boxes indicate men, circles indicate women, and affected individuals are pointed out in black. The arrows indicate the probands. Double lines point out consanguineous marriages, the numbers indicate the degree of consanguinity. The dagger (†) indicates the patients diagnosed with RP not included in this study due the lack of clinical data.

Clinical Evaluation

The most recent examination of the 17 RP patients was performed at a mean age of 49 years (range, 23–67 years). The mean age at onset was 10.5 years (range, 4–20 years), and night blindness was the most frequent initial symptom, occurring in 10 patients (59%). Other initial symptoms were decrease in visual acuity (35%) and loss of visual field (6%). In the patients

who initially revealed a decreased visual acuity, normal BCVA was measured before the decrease in visual acuity, which excludes refractive amblyopia. In one patient (A-II:6), the diagnosis of RP was made during a routine ophthalmologic consultation when he was 12 years old. At that time, he had not noticed any symptoms associated with RP, but later in the course of the dystrophy, night blindness manifested as the first

TABLE 1. Clinical Findings in Patients With *IMPG2*-Associated RP at Their Most Recent Visit

Family*	Patient ID/ AaO, y/ Age, y/Sex	Initial Symptom	Visual Acuity†				SER (D)‡		Ophthalmoscopy Results		ERG Results	
			OD	OS	OD	OS	OD	OS	Scotopic	Photopic		
A (W01-299)	A-II:1/8/59/F	Decrease in visual acuity	LP (2.7)	LP (2.7)	-4.00	-4.00	-4.00	-4.00	BEM, optic disc paleness, peripapillary atrophy, vessel attenuation, RPE atrophy and bone spicule pigmentations in the periphery.	NR (ages 8 and 27)	NR (ages 8 and 27)	
A (W01-299)	A-II:5/14/45/ M	Loss of visual field	20/200 (1.0)	LP (2.7)	-0.25	-0.25	-0.25	-0.25	Subtle BEM, ERM, peripapillary atrophy, optic disc pallor, attenuated vessels. Periphery: sheathing of the vessels, RPE atrophy and bone spicule pigmentations.	SR (ages 14 and 30)	SR (ages 14 and 30)	
A (W01-299)	A-II:6/12/44/ M	None, after diagnosis night blindness	20/120 (0.8)	20/400 (1.3)	plan	-0.25	-0.25	-0.25	BEM, peripapillary atrophy, pale optic disc, attenuated vessels, RPE atrophy and bone spicule pigmentations in the periphery.	SR (ages 12 and 23)	SR (ages 12 and 23)	
B (MOL0764)	B-II:1/ Child- hood/66/F	Decrease in visual acuity	LP (2.7)	LP (2.7)	-12.00	-11.75	-11.75	-11.75	Posterior staphyloma, macular atrophy, optic disc paleness, attenuated vessels, RPE atrophy with bone spicules in periphery	NR	NR	
B (MOL0764)	B-II:2/ Child- hood/60/F	Decrease in visual acuity	HM (2.3)	HM (2.3)	-8.25	-5.50	-5.50	-5.50	Myopic changes, RPE atrophy in posterior pole, optic disc pallor, attenuated vessels, RPE atrophy and bone spicules in periphery.	NR	NR	
B (MOL0764)	B-II:3/ Child- hood/52/F	Decrease in visual acuity	CF (1.9)	CF (1.9)	-3.00	-3.25	-3.25	-3.25	RPE atrophy in posterior pole, pallor of the optic disc, attenuated vessels, RPE atrophy and bone spicules in the periphery.	NR	NR	
C (W08-1378)	C-II:2/8/33/M	Night blindness	20/50 (0.4)	20/50 (0.4)	-5.50	-7.00	-7.00	-7.00	Mottling of macular RPE, optic disc pallor, subtle peripapillary atrophy, vessel attenuation, midperipheral bone spicules.	NR	NR	
C (W08-1378)	C-II:3/8/36/M	Night blindness and decreased color vision	20/50 (0.4)	CF (1.9)	-4.00	-4.50	-4.50	-4.50	Macular atrophy with pigment changes, peripapillary atrophy, waxy optic disc, bone spicule pigmentations in the midperiphery.	NR	NR	
D (NAP1)	D-II:1/20/65/ F	Night blindness	HM (2.3)	HM (2.3)	NP	NP	NP	NP	Macular atrophy, pallor of the optic disc, attenuation of the vessels, RPE atrophy and bone spicule in the periphery.	NR	NR	

TABLE 1. Extended

Family*	Patient ID/ AaO, y/ Age, y/Sex	Goldmann Perimetry	OCT Results	Autofluorescence Results	Follow-up, y
A (W01-299)	A-II:1/8/59/F	NP	Severely thinned retina, generalized loss of the outer retina, central RPE residue with parafoveal RPE atrophy	NP	48
A (W01-299)	A-II:5/14/45/M	Constricted to 10° with moderately sensitivity loss.	Generalized loss of reflectance of the outer retinal layers, irregular reflective spots just above the RPE reflective band, lowered parafoveal RPE reflectance, ERM with minimal traction inferior of the fovea.	Irregular hypoAF in the macula, normofluorescent aspect surrounding the macula giving the impression of a hyperAF ring, mottled aspect of hypoAF in the midperiphery.	28
A (W01-299)	A-II:6/12/44/M	Constricted to 10° with moderately sensitivity loss.	Generalized loss of the outer retinal layers, RPE reflectance fairly intact, except in the temporal parafovea.	Granular hypoAF aspect of the macula, perifoveal deep hypoAF signal giving the impression of a bull's eye-like aspect, normofluorescent aspect surrounding the macula giving the impression of a hyperAF ring, mottled aspect of hypoAF and larger hypoAF lesions in the midperiphery.	19
B (MOL0764)	B-II:1/ Child-hood/66/F	Constricted VF up to less than 5°.	Severely thinned central retina.	NP	0
B (MOL0764)	B-II:2/ Child-hood/60/F	Constricted VF up to 5°.	Severe thinning of central retina, atrophy of the choriocapillaris.	HypoAF macula and peripapillary region, granular hypoAF aspect of midperiphery.	0
B (MOL0764)	B-II:3/ Child-hood/52/F	Peripheral island	NP	NP	0
C (W08-1378)	C-II:2/8/33/M	Mildly decreased sensitivity with absolute nasal paracentral scotomas	NP	NP	0
C (W08-1378)	C-II:3/8/36/M	Mildly decreased sensitivity, relative and absolute scotomas in the midperiphery, temporal paracentral scotoma.	NP	NP	0
D (NAP1)	D-II:1/20/65/F	NP	NP	NP	0

TABLE 1. Continued

Family*	Patient ID/ AaO, y/ Age, y/Sex	Initial Symptom	Visual Acuity†				SER (D)‡		Lens Status	Ophthalmoscopy Results	ERG Results	
			OD	OS	OD	OS	OD	OS			Scotopic	Photopic
E (NAP75)	E-II:4/4/63/F	Night blindness	CF (1.9)	HM (2.3)	NP	NP	NP	Pseudophakia in both eyes	Macular atrophy, ERM, waxy pallor of the tilted optic disc, attenuated vessels, peripheral RPE atrophy and bone spicules.	NR	NR	
F (RP49)	F-II:1/12/23/ M	Night blindness	20/120 (0.8)	20/40 (0.3)	-1.00	-3.00	Clear	Clear	Parafoveal atrophy, the optic disc pallor (LE > RE), narrow vessels, few bone spicules in the midperiphery.	NR	NR	
F (RP49)	F-II:2/10/52/F	Night blindness	20/120 (0.8)	20/100 (0.7)	-5.75	-6.50	Clear	Clear	BEM, ERM, waxy pallor of the optic disc, vessel attenuation (RE > LE), bone spicule pigmentations, generalized retinal degeneration.	NP	NP	
G	G-II:1/17/60/ M	Night blindness	20/300 (1.2)	20/300 (1.2)	-2.00	-3.00	Clear	Clear	Macular atrophy, peripapillary atrophy, bone spicule pigmentations, waxy optic disc, narrow vessels, generalized chorioretinal atrophy.	NR	SR	
G	G-II:6/16/59/ F	Night blindness	20/30 (0.2)	20/40 (0.3)	-6.00	-7.00	CN cataract	CN cataract	BEM, peripapillary atrophy, waxy optic disc, narrow vessels. Periphery: bone spicule pigmentations and chorioretinal atrophy.	NR (age 37)	NR (age 37)	
H	H-II:6/17/46/ F	Night blindness	CF (1.9)	20/200 (1.0)	-5.00	-3.75	Cataract extracted at age 35 (RE) and 39 (LE)	Cataract extracted at age 35 (RE) and 39 (LE)	Small central area with spared RPE, fovea dark compared to perfovea, but no evident bull's eye, moderate/severe pallor optic disc, severely attenuated vessels, Periphery: bone spicules and drusenoid deposits.	NR (age 34)	NR (age 34)	
J	J-II:1/4/23/F	Decrease in visual acuity	20/40 (0.3)	20/40 (0.3)	Plan	Plan	Mild cortical opacities	Mild cortical opacities	Mottled macula, moderate pallor, moderate attenuated vessels, RPE atrophy and bone spicules anterior of vascular arcades.	SR (age 18)	SR (age 18)	

TABLE 1. Continued Extended

Family*	Patient ID/ AaO, y/ Age, y/Sex	Goldmann Perimetry	OCT Results	Autofluorescence Results	Follow-up, y
E (NAP75)	E-II:4/4/63/F	NP	Thinned retina, increased beam penetrance in the fovea due to RPE loss (TD-OCT).	NP	0
F (RP49)	F-II:1/12/23/M	Constriction to 20° or midperipheral scotoma (only central 30° was tested), paracentral scotoma in LE, mildly decreased sensitivity (Humphrey)	Severe thinning of central retina (TD-OCT).	NP	0
F (RP49)	F-II:2/10/32/F	Constriction to 20° or midperipheral scotoma (only central 30° was tested), moderately decreased sensitivity (Humphrey)	Severe thinning of central retina (TD-OCT).	NP	0
G	G-II:1/17/60/M	Constricted to 20° with inferior residue, severely decreased central sensitivity.	Generalized loss of the bands corresponding to the photoreceptor inner and outer segments, a thinned ONL, patchy loss/thinning of the foveal RPE; profound loss of the outer retina, RPE and choriocapillaris reflectance in the midperiphery.	HypoAF macula, granular hypoAF aspect with large confluent hypoAF lesions in the midperiphery; peripapillary hypoAF.	34
G	G-II:2/16/59/F	Constricted to 20° with residue inferior. Sensitivity very mildly decreased.	Fairly intact foveal laminar retinal architecture, confluence of the bands corresponding to the ellipsoid inner segments and the RPE, ELM reflectance is present only in the fovea, thinned ONL outside the fovea, minimal CME in the LE, the RPE seems fairly intact except for irregular thinning the fovea and RPE loss in the peripapillary region; profound loss of the outer retinal, RPE, and choriocapillaris reflectance in the midperiphery.	2 small hypoAF spots in the otherwise hyperAF macula, subtle hyperAF ring around macula, granular aspect with sporadic hypoAF lesion just anterior of the vascular arcades, prominent blockage of AF by bone spicules.	34
H	H-II:6/17/46/F	Constricted to <10°, moderately decreased central sensitivity, small inferotemporal residues	Severely thinned central retina, small central residue of the ONL, fairly intact RPE reflectance in the fovea.	HyperAF macula, mottled aspect of hypoAF and larger hypoAF lesions just anterior of the vascular arcades, peripapillary hypoAF.	16
J	H-II:6/17/46/F	Constricted to 40° with temporal residual VE, mildly decreased central sensitivity in RE, severely decreased central sensitivity in LE.	Loss of the bands corresponding to the photoreceptor inner and outer segments, severely thinned ONL outside the fovea, irregular reflectance of presumably the ELM in the foveola. RPE reflectance intact in central retina.	Irregular hyperAF in macula (LE > RE), sporadic small hypoAF spots just anterior of the vascular arcades.	14

TABLE 1. Continued

Family*	Patient ID/ AaO, y/ Age, y/Sex	Initial Symptom	Visual Acuity†			SER (D)‡		Lens Status	Ophthalmoscopy Results	ERG Results	
			OD	OS	OS	OD	OS			Scotopic	Photopic
K	K-II:1/4/67/F	Decrease in visual acuity	20/400 (1.3)	20/400 (1.3)	−4.25	−3.50	Pseudophakia in RE, mild cataract in LE.	BEM, pallor of the optic disc, peripapillary pigmentation, severely attenuated vessels, RPE atrophy, and intraretinal bone spicule pigmentations in the midperiphery.	SR (age 24)	WNL (age 24)	

AaO, Age at onset; CF, counting fingers; CME, cystoid macular edema; CN, corticonuclear; D, diopters; ELM, external limiting membrane; ERM, epiretinal membrane; F, female; HM, hand movements; IS, inner segments; LE, left eye; LP, light perception; M, male; MR, moderately reduced; NP, not performed; NR, nonrecordable; OCT, optical coherence tomography; ONL, outer nuclear layer; OS, outer segments; PSC, posterior subcapsular; RE, right eye; SER, spherical equivalent refraction; SR, severely reduced; TD, time-domain; VF, visual field.

* The family ID between brackets are those used before in reference 13. For readability issues, we preferred one-letter family IDs.

† The visual acuity is noted in both Snellen visual acuity and logMAR visual acuity (between brackets).

‡ If cataract surgery has been performed, the presurgery SER was noted.

TABLE 1. Continued Extended

Family*	Patient ID/ AaO, y/ Age, y/Sex	Goldmann Perimetry	OCT Results	Autofluorescence Results	Follow-up, y
K	K-II:1/4/67/F	NP	Loss of the bands corresponding to the photoreceptor inner and outer segments, severely thinned ONL in the central retina, RPE reflectance intact except for in the parafovea.	Mottled hypoAF aspect of the perifoveal region, hyperAF in the fovea, mottled hypoAF aspect just anterior of the vascular arcades.	41




FIGURE 2. Graph showing the change in visual acuity (y -axis) related to the age in years (x -axis) in patients carrying mutations in the *IMPG2* gene. Snellen visual acuity was transformed into logMAR for visualization purposes. A logMAR value of 1.9 was assigned to counting fingers (CF), 2.3 to hand movements (HM), and 2.7 to light perception (LP). When the visual acuity differed in both eyes, the visual acuity of the best eye was used. The improvement in visual acuity in patient A-II:5 was seen after cataract surgery; subsequently, the decrease in visual acuity was probably due to cystoid macular edema, which was successfully treated. The cause of the improvement in patient J-II:1 is unclear, because refractive, optical, or retinal causes seemed absent.

symptom at age 24. In eight patients, an extended clinical follow-up period varying from 14 to 48 years was available (mean: 29 years). The course of the BCVA for each of these patients during follow-up is represented in Figure 2. None of the patients showed extraocular abnormalities that are indicative of syndromic RP.

Refractive errors included mild to high myopia (range of spherical equivalents: plan to -12.00 diopters; Table 1). Significant lens opacities were observed in 13 patients, most

often subcapsular posterior cataracts (seven patients [41%], Table 1). Six patients had experienced cataract surgery, most often in the fourth decade (five of six patients). Ophthalmoscopy revealed the classic RP features, including bone spicule pigmentation at the (mid)periphery, attenuated vessels, waxy pallor of the optic disc, and atrophy of the RPE and choriocapillaris in all RP patients. In one patient (A-II:5), marked sheathing of the peripheral retinal vessels was noted (Fig. 3A). In addition, all patients revealed macular abnormal-




FIGURE 3. Fundus photographs and FAF imaging of patients carrying mutations in *IMPG2*. (A and F) Fundus photograph of temporal superior region of the retina (A), showing sheathing of the retinal vessels, and FAF imaging of the central retina (F), revealing irregular FAF signal in the macula and a granular hypoautofluorescent aspect of the RPE surrounding the posterior pole, in patient A-II:5 (age 45). (B and H) Fundus photograph composition (B), showing macular atrophy, and FAF images (H), revealing a hypoautofluorescent macula, a granular aspect with large confluent hypoautofluorescent lesions in the midperiphery, and peripapillary hypoautofluorescence, of patient G-II:1 (age 60). (C and E) Fundus photograph (C) and FAF image (E) of the central retina in patient A-II:6 (age 44). The fundus photograph reveals a BEM. The FAF image shows granular aspect of the macula, whereas deeper perifoveal hypoautofluorescence gives the impression of a BEM, mottled aspect of midperiphery with larger hypoautofluorescent lesions. (D and G) Fundus photograph (D) and FAF image (G) of the central retina in patient K-II:1 (age 67). The fundus photograph shows a BEM, whereas FAF reveals a mottled hypoautofluorescent aspect of the perifoveal region, hyperautofluorescence in the fovea, and a mottled aspect just anterior of the vascular arcades.




FIGURE 4. Multimodal imaging of the central retina in patient G-II:2 at the age of 59. (A) Fundus photograph showing a BEM, attenuated vessels, peripapillary atrophy, pale optic disc, bone-spicule pigmentations, and chorioretinal atrophy in the midperiphery. (B) Autofluorescence imaging shows a subtle hyperautofluorescent ring around the macula, spots of decreased macular and peripheral autofluorescence, and absence of autofluorescence corresponding with the peripapillary atrophy. (C) Spectral domain OCT reveals loss of the bands corresponding to the photoreceptor inner and outer segments in the macula. The external limiting membrane is present only in the fovea. The RPE layer seems fairly intact, except for irregular thinning in the fovea and loss of RPE in the peripapillary region. (D) Infrared en face image reveals the location of the SD-OCT image (green line).

ities ranging from subtle changes, such as mottling of the macular RPE as observed in C-II:2 and J-II:1, to profound macular atrophy as was observed in seven patients (mean age: 57 years; range, 36–66, Fig. 3B). A bull's eye maculopathy (BEM) was a distinctive ophthalmoscopic feature in six patients, which mainly was observed during the fifth and sixth decades of life (mean age: 51 years; range, 32–67 years, Figs. 3C, 3D, 4A). Since the exact onset of the BEM could not be ascertained, we were unable to define the interval in which the BEM had been present in these patients. Progression of a BEM to atrophy covering the whole fovea was observed in the follow-up data of patient G-II:1.

Perimetry revealed visual field constriction resulting in tunnel vision of 20° or less in nine patients (mean age: 48 years; range, 23–66 years; Fig. 5). Macular involvement was apparent by a gradual decrease in central sensitivity, which we observed in 10 patients (mean age: 40 years; range, 23–66 years). We observed paracentral scotomas in two patients (C-II:2 and C-II:3) with a relatively intact (mid)peripheral visual field (Fig. 5C). Additionally, paracentral scotomas were present in patients F-II:1 and F-II:2, in whom only the central 30° was analyzed with the more sensitive static perimeter (Table 1). Electroretinographic responses were nonrecordable in 11 patients (mean age: 51 years). In five patients (mean age: 31 years), a severely reduced photoreceptor dysfunction was seen in a rod-cone pattern. Evaluation of color vision resulted in an isolated tritan defect in patients A-II:6, G-II:1, and G-II:2 at ages

24, 40, and 39, respectively, whereas patients C-II:2 and C-II:3 demonstrated strong protan, deutan, and tritan defects at ages 33 and 36, respectively. In patient A-II:5, we did not detect color vision defects.

Fundus autofluorescence (FAF) images revealed macular involvement in all eight patients for whom FAF imaging was available. The macular aspects varied from hyperautofluorescence to profound hypoautofluorescent RPE lesions (mean age: 51 years; range, 23–67 years, Figs. 3E–G, 3I, 4B). Midperipheral changes include granular or mottled hypoautofluorescent changes that are spread to the vascular arcades. In some patients, large (confluent) hypoautofluorescent lesions were observed just anterior of the vascular arcades (Figs. 3E, 3H). Evaluation of the central retinal structure with SD-OCT revealed loss of photoreceptors before RPE cell loss, which eventually result in moderate to severe retinal thinning (Fig. 6A). The foveal volume in seven Dutch RP patients (mean age: 49 years; range, 23–67) was significantly lower compared with the foveal volume in 25 age-matched Dutch healthy controls ($P < 0.0001$; Fig. 6B). In all patients with high-resolution SD-OCT, except in G-II:2, the bands corresponding to the photoreceptor inner and outer segments were lost.²⁴ The outer nuclear layer, containing the photoreceptor cell bodies, was concentrically lost and severely thinned where present. We observed concentric atrophy of the layer that corresponds to the RPE cells that progressed from the midperiphery. The central abnormalities in the RPE layer started in the parafoveal region,




FIGURE 5. Goldmann perimetry findings in the right eyes of patients J-II:1 (age 23, A), H-II:2 (age 35, B), C-II:3 (age 37, C), and G-II:2 (age 59, D). The colored lines indicate the outer borders of the isopters. The filled areas indicate scotomas for the isopter of that color.

as was observed in four patients who also revealed a BEM (Fig. 6D). In patient J-II:1, who displayed mottling in the macula, the RPE appeared normal on SD-OCT (Fig. 6E). In later stages of the disease, we observed loss of the foveal RPE layer, which was highlighted by a increased beam penetration and choroidal reflection in patients E-II:4 and G-II:1 (Fig. 6F). Spectral-domain OCT scans in the midperiphery revealed loss of the photoreceptor-RPE complex and intraretinal pigment deposits in patients G-II:1 and G-II:2 at ages 60 and 59, respectively (Fig. 6G), whereas patient J-II:1 at the age of 23 revealed only photoreceptor loss (Fig. 6H).

Mutation Analysis

A description of the molecular genetic findings in families A to F were reported earlier.¹³ In summary, sequence analysis of all 19 coding exons of *IMPG2* led to the identification of 10 different pathogenic variants in these 17 patients (Table 2). In the families with available family members, the homozygous or compound heterozygous mutations segregated completely with the RP phenotype (Fig. 1).¹³

In addition to the mutations described earlier,¹³ four new pathogenic variants in *IMPG2* were identified. In family G, a targeted next-generation sequencing approach that covered 111 blindness genes resulted in two compound heterozygous mutations: a nonsense mutation (p.Arg127*), which is predicted to cause premature truncation of the *IMPG2* protein, and a 4-base-pair deletion (c.3423-8_c.3423-5del) that affects the splice acceptor site (Table 2).²² Reverse transcriptase PCR analysis on RNA isolated from patients' lymphoblastoid cells revealed that, instead of the regular splice acceptor site, a second splice site located upstream in the same intron is used that results in the inclusion of 80 additional nucleotides to *IMPG2* mRNA, subsequently leading to a frameshift and premature termination of *IMPG2* (Supplementary Fig. S1). The cDNA products generated from RNAs isolated from cells grown under nonsense-mediated decay (NMD)-suppressing conditions show subtle differences compared with those generated from RNAs isolated from cells grown under normal conditions. Growing cells under NMD-suppressing conditions

did not yield an obvious difference in the amount of aberrantly spliced *IMPG2*, indicating that a truncated protein may be produced. The other novel mutations include a nonsense mutation (p.Tyr171*) and a missense mutation (p.Ser379Pro). The nonsense mutation is predicted to cause a premature truncation of *IMPG2*. The p.Ser379Pro missense mutation changes a highly conserved amino acid and is unanimously predicted to be pathogenic by multiple in silico prediction tools (SIFT: deleterious [score: 0], PolyPhen-2: probably damaging [score: 1.000], Align GVGD: Class C65, MutationTaster: disease causing [probability: 0.994], Grantham score: 74, PROVEAN prediction: deleterious [score: -2.972]).

DISCUSSION

The Phenotype of *IMPG2*-Associated RP

In this study, we provide a detailed clinical description of the RP associated with mutations in *IMPG2*, a gene that recently was added to the long list of genes that may cause autosomal recessive RP when mutated.¹³ Most of the patients with *IMPG2*-associated RP demonstrated the classic RP symptoms: night blindness and progressive concentric loss of the visual field. However, 6 of 17 patients mentioned a decrease in BCVA that could not be attributed to amblyopia as the initial symptom. Loss of vision as the initial symptom is not just a result of our electrically illuminated nighttime environment that compensates for an impaired night vision,^{4,5} but a consequence of macular abnormalities that are a prominent feature of this type of RP. Overall, the BCVA progressively decreased during the first 4 decades of life, and subsequently deteriorates to levels lower than 20/300 during the fifth and sixth decades of life. The only exception was patient G-II:2, who still enjoyed a BCVA of 20/30 at the age of 59.

Thirteen of the 17 RP patients included in this study showed significant macular abnormalities: a BEM was observed in six patients (mean age: 51 years) and profound macular atrophy in seven patients (mean age: 57 years). We hypothesize that the perifoveal atrophy, manifesting as a bull's eye pattern,




FIGURE 6. Optical coherence tomography examinations in patients with *IMPG2*-associated RP. (A) Thickness of the total retina in eight Dutch patients (mean age: 49 years; range, 23–67). *Shaded areas*: normal limits (mean \pm 2 SDs) as measured in 25 controls (mean age: 46 years). (B) Foveal volume (mm^3) measured in the central 3 mm^2 in these patients except patient A-II:1. The foveal volume in seven Dutch *IMPG2*-associated RP patients (mean age: 49 years; range, 23–67) was significantly lower than in 25 age-matched healthy Dutch controls ($P < 0.0001$). The horizontal bars indicate the median of the corresponding cohort. (C) Spectral-domain OCT scan of a normal central retina (age 25). The hyperreflective bands correspond to the external limiting membrane (1), the ellipsoid photoreceptor inner segments (2), the photoreceptor outer segment/RPE contact cylinder region (3), and the RPE (4).²⁴ (D) Spectral-domain OCT of patient A-II:6 (age 44) that reveals generalized loss of the outer retinal layers, whereas the RPE reflectance is fairly intact except for the irregular signal and thinning in the temporal parafovea (*white arrowhead*). (E/H) Spectral-domain OCT in patient J-II:1 (age 23). The central retina (E) revealed normal bands corresponding to the RPE, whereas the photoreceptor bands are absent outside the fovea. The midperipheral retina (H) reveals loss of the photoreceptor inner and outer segment bands. However, no profound RPE atrophy or intraretinal pigment deposits were observed yet. (F and G) Spectral-domain OCT of patient G-II:1 (age 60). The central retina (F) reveals generalized loss of photoreceptor inner and outer segments, a thinned outer nuclear layer, and patchy loss/thinning of the foveal RPE. The midperipheral retina (G) shows profound loss of the outer retinal layers, RPE and choriocapillaris reflectance, as well as intraretinal pigment deposits.

eventually progresses to macular atrophy with profound degeneration of photoreceptors and RPE, although this was observed only in patient G-II:1 because longitudinal data of the other patients with macular atrophy were not available. The 13 patients with macular involvement displayed a decreased central sensitivity and/or paracentral scotomas on visual field examination in addition to the concentric constriction that is typically seen in RP (Table 1; Fig. 5). Spectral-domain OCT of the macula showed early loss of photoreceptor inner and outer segments before loss of the RPE layer in the central retina. On FAF imaging, macular hypoautofluorescence was observed, whereas hypoautofluorescence in the midperiphery generally had a granular aspect. In contrast to the significant macular involvement that was observed in most patients, subtle macular FAF abnormalities appeared in patients C-II:2 and J-II:1. However, subtle macular FAF abnormalities have been observed in other forms of RP with intact central vision and therefore do not automatically predate loss of macular function.²⁵

A BEM is a nonspecific reaction of the posterior pole, which can occur in various diseases affecting the bipolar cell layer,

photoreceptor cell layer, or RPE.²⁶ It is not often observed in RP, but has been reported in some specific forms of syndromic and nonsyndromic RP,^{27–31} and is associated with a faster deterioration of the visual acuity compared with RP without specific macular lesions.³² Concerning the BEM in *IMPG2*-associated RP, multimodal imaging revealed abnormalities in the photoreceptor and RPE cell layers. However, it is unclear why RPE abnormalities initially predominate in the perifoveal region, as the preceding abnormalities in the photoreceptor layer are ubiquitously present. Possible explanations may include topographical differences in metabolism and cell densities,³³ the higher vulnerability of S (“blue”) cone photoreceptors to retinal disease compared with M and L cones,³⁴ and the higher vulnerability of parafoveal rods to aging and light-induced damage.^{35–37} In patient G-II:2 (age 59), we observed a prominent BEM due to hypopigmentation rather than atrophy of the perifoveal RPE, as there were only minor RPE changes on FAF imaging (Fig. 4B) and mild changes of the band corresponding to the photoreceptor outer segment–RPE complex (Fig. 4C). By contrast, other patients with BEM revealed perifoveal hypoautofluorescence indicating

TABLE 2. Mutations Identified in the *IMPG2* Genes in the Patients With Inherited Retinal Disease Included in This Study

ID	Inheritance	Origin	Allele 1			Allele 2			Type of Mutations	Consanguinity
			cDNA Variant	Effect	Effect	cDNA Variant	Effect	Effect		
A-II:1	AR	Dutch	c.888-1554_908+274del	p.Arg296_Asp302 del	c.888-1554_908+274del	p.Arg296_Asp302 del	Deletion	None		
A-II:5	AR	Dutch	c.888-1554_908+274del	p.Arg296_Asp302 del	c.888-1554_908+274del	p.Arg296_Asp302 del	Deletion	None		
A-II:6	AR	Dutch	c.888-1554_908+274del	p.Arg296_Asp302 del	c.888-1554_908+274del	p.Arg296_Asp302 del	Deletion	None		
B-II:1	AR	Iraqi Jew	c.635C→G	p.Ser212*	c.635C→G	p.Ser212*	Nonsense	First cousins		
B-II:2	AR	Iraqi Jew	c.635C→G	p.Ser212*	c.635C→G	p.Ser212*	Nonsense	First cousins		
B-II:3	AR	Iraqi Jew	c.635C→G	p.Ser212*	c.635C→G	p.Ser212*	Nonsense	First cousins		
C-II:2	AR	Dutch	c.2716C→T	p.Arg906*	c.2716C→T	p.Arg906*	Nonsense	Second cousins		
C-II:3	AR	Dutch	c.2716C→T	p.Arg906*	c.2716C→T	p.Arg906*	Nonsense	Second cousins		
D-II:1	AR	Italian	c.2890C→T	p.Arg964*	c.2890C→T	p.Arg964*	Nonsense	Second cousins		
E-II:4	Isolated	Italian	c.3262C→T	p.Arg1088*	c.3262C→T	p.Arg1088*	Nonsense	Second cousins		
F-II:1	AR	Pakistan	c.1680T→A	p.Tyr560*	c.1680T→A	p.Tyr560*	Nonsense	First cousins		
F-II:2	AR	Pakistan	c.1680T→A	p.Tyr560*	c.1680T→A	p.Tyr560*	Nonsense	First cousins		
G-II:1	AR	Dutch	c.379G→A	p.Arg127*	c.3423-8_c.3423-5del	Splicing	Nonsense/Deletion	Second cousins		
G-II:2	AR	Dutch	c.379G→A	p.Arg127*	c.3423-8_c.3423-5del	Splicing	Nonsense/Deletion	Second cousins		
H-II:2	AR	Dutch	c.513T→G	p.Tyr171*	c.2716C→T	p.Arg906*	Nonsense	None		
J-II:1	Isolated	Dutch	c.2716C→T	p.Arg906*	c.2716C→T	p.Arg906*	Nonsense	None		
K-II:1	Isolated	Dutch	c.1135T→C	p.Ser379Pro	c.2716C→T	p.Arg906*	Nonsense	None		

Nonsense mutations change a DNA codon for an amino acid in a stop codon, inducing a premature truncation of the protein. Deletions remove one or more nucleotides from the DNA, which can alter the reading frame. In these cases, the deletions cause frameshifts and prematurely truncated proteins. Missense mutations change a DNA codon for an amino acid in a codon for another amino acid. These mutations can have structural or functional effects on the protein, depending on the domain in which the mutation occurs. Missense mutations generally have less-severe effects on protein function when compared with nonsense mutations or frameshift-inducing deletions. The p.Arg906* mutation was identified frequently in the Dutch patients included in this study (9/22 alleles, 41%) and may be a Dutch founder mutation. AR, autosomal recessive; NI, not identified; del, deletion; *, premature stop.

perifoveal RPE atrophy (Figs. 3E, 3G). In late stages of the disease, profound macular hypoautofluorescence developed, which is indicative of RPE atrophy (Fig. 3H). In the light of future therapeutic options for retinal dystrophies, knowledge of the natural course of *IMPG2*-associated retinal disease is necessary to select patients amenable for treatment and to correctly interpret the effect of therapeutic intervention.

Genotype-Phenotype Correlation

Bandah-Rozenfeld et al.¹³ identified mutations only with severe effects on the *IMPG2* protein in RP patients, whereas a homozygous mild missense mutation was identified in one patient with a mild maculopathy. In families G to K, we identified two novel truncating nonsense mutations (families G and H), a deletion causing a splice defect (family G), and a missense mutation that is unanimously predicted to be pathogenic (family K). The function of *IMPG2* is vital for retinal survival and function, as most *IMPG2* mutations that are identified in our patients can be considered true loss-of-function alleles. Until now, only one homozygous mild (missense) mutation in *IMPG2* has been described in a single patient with an isolated maculopathy and a mildly affected visual function.¹³ This might indicate that a minimal loss of function of the *IMPG2* protein may result in mild or even absent retinal disease.

Each of the seven nonsense mutations lead to either mRNA breakdown because of nonsense-mediated decay, or predicted truncated *IMPG2* proteins that all lack the transmembrane domain and the cytoplasmic tail. The in-frame deletion identified in family A (c.888-1554_908+274del; absence of seven amino acids) is thought to result in a nonfunctional *IMPG2* protein, as in a cellular transfection assay this mutant protein was retained in the endoplasmic reticulum, whereas *IMPG2* is physiologically located in the cell membrane.¹³ The 4-base-pair deletion of the splice acceptor site in family G (c.3423-8_c.3423-5del) was found to result in the use of an alternative splice acceptor site, and thereby also predicted to result in the generation of a truncated protein that most likely has reduced or no remaining function. Interestingly, the p.Arg906* was present in 8 of 20 alleles (40%) in 10 Dutch patients, which may imply a founder mutation in the Dutch population.

Because the identified mutations cause (near-)complete loss of *IMPG2* function, the clinical variation is limited in *IMPG2*-associated RP. The patients in family G, however, retained slightly better visual acuity and visual field compared with the other patients (Fig. 2; Table 1). This could imply that the splice defect in this family results in an *IMPG2* protein with some residual function. However, functional assays are needed to reveal the true effect of the c.3423-8_c.3423-5 deletion, as there also is evidence of modifying factors in this family (Table 1; Figs. 2, 3B, 3H, 4) that influence the intrafamilial differences.

The *IMPG2* protein (SPACRCAN) is highly homologous to SPACR, the product of the interphotoreceptor matrix proteoglycan 1 (*IMPG1*) gene, which has been linked to benign concentric annular macular dystrophy (BCAMD) and vitelliform macular dystrophy (VMD).^{38,39} Interestingly, BCAMD includes parafoveal hypopigmentation and RP-like fundoscopic changes in the end-stage disease, although visual acuity is generally better preserved than in the *IMPG2*-associated RP patients in this report.³⁸ The *IMPG1*-associated vitelliform dystrophy is also associated with macular pathology, although this is characterized by accumulation of lipofuscin rather than a BEM.³⁹

In conclusion, severe mutations in *IMPG2* are the cause of an autosomal recessive RP phenotype that manifests in the early teens and is accompanied by atrophic maculopathy often

in a bull's eye pattern. In early disease stages, the maculopathy is characterized by mild RPE alterations, but in later stages of the disease, a BEM and profound macular chorioretinal atrophy may occur. In most patients, the RP phenotype arising from mutations in the *IMPG2* gene is severe, because of the unfortunate combination of progressive constriction of the visual fields and maculopathy that occurs relatively early in the course of the disease.

Acknowledgments

We thank all patients included in this study. We also thank Linda Visser and Annemiek Krijnen for their help regarding the clinical data of the Dutch patients from the Rotterdam Eye Hospital.

Supported by the Stichting A.F. Deutman Researchfonds Oogheelkunde, Nijmegen, The Netherlands (BJK), Grants BR-GE-0510-0489-RAD (AldH) and C-GE-0811-0545-RAD01 from the Foundation Fighting Blindness USA (FPMC, RWJC, AldH), the Stichting Wetenschappelijk Onderzoek Het Oogziekenhuis Prof Dr H.J. Flieringa (LlvdB, AldH, FPMC), and The Netherlands Organization for Health Research and Development (ZonMW; TOP-Grant 40-00812-98-09047 [AldH, FPMC]). The funding organizations had no role in the design or conduct of this research.

Disclosure: **R.A.C. van Huet**, None; **R.W.J. Collin**, None; **A.M. Siemiatkowska**, None; **C.C.W. Klaver**, None; **C.B. Hoyng**, None; **F. Simonelli**, None; **M.I. Khan**, None; **R. Qamar**, None; **E. Banin**, None; **F.P.M. Cremers**, None; **T. Theelen**, None; **A.I. den Hollander**, None; **L.I. van den Born**, None; **B.J. Klevering**, None

References

1. Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. *Am J Ophthalmol*. 1984;97:357-365.
2. Rosenberg T. Epidemiology of hereditary ocular disorders. *Dev Ophthalmol*. 2003;37:16-33.
3. Berson EL. Retinitis pigmentosa. The Friedenwald Lecture. *Invest Ophthalmol Vis Sci*. 1993;34:1659-1676.
4. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. *Lancet*. 2006;368:1795-1809.
5. Hamel C. Retinitis pigmentosa. *Orphanet J Rare Dis*. 2006;1:40.
6. Dryja TP, Hahn LB, Kajiwarra K, Berson EL. Dominant and digenic mutations in the peripherin/RDS and ROM1 genes in retinitis pigmentosa. *Invest Ophthalmol Vis Sci*. 1997;38:1972-1982.
7. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. *Prog Retin Eye Res*. 2008;27:391-419.
8. Schrier SA, Falk MJ. Mitochondrial disorders and the eye. *Curr Opin Ophthalmol*. 2011;22:325-331.
9. Kajiwarra K, Berson EL, Dryja TP. Digenic retinitis pigmentosa due to mutations at the unlinked peripherin/RDS and ROM1 loci. *Science*. 1994;264:1604-1608.
10. den Hollander AI, Black A, Bennett J, Cremers FP. Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. *J Clin Invest*. 2010;120:3042-3053.
11. Neveling K, Feenstra I, Gilissen C, et al. A post-hoc comparison of the utility of sanger sequencing and exome sequencing for the diagnosis of heterogeneous diseases. *Hum Mutat*. 2013;34:1721-1726.
12. Berger W, Kloeckener-Gruissem B, Neidhardt J. The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin Eye Res*. 2010;29:335-375.

13. Bandah-Rozenfeld D, Collin RW, Banin E, et al. Mutations in *IMPG2*, encoding interphotoreceptor matrix proteoglycan 2, cause autosomal-recessive retinitis pigmentosa. *Am J Hum Genet.* 2010;87:199–208.
14. Inatani M, Tanihara H. Proteoglycans in retina. *Prog Retin Eye Res.* 2002;21:429–447.
15. Adler AJ, Klucznik KM. Proteins and glycoproteins of the bovine interphotoreceptor matrix: composition and fractionation. *Exp Eye Res.* 1982;34:423–434.
16. Hageman GS, Johnson LV. Structure, composition and function of the retinal interphotoreceptor matrix. In: Osborne N, Chader G, eds. *Retinal Research*. New York: Pergamon Press; 1991:207–249.
17. Berman ER. Mucopolysaccharides (glycosaminoglycans) of the retina: identification, distribution and possible biological role. *Bibl Ophthalmol.* 1969;79:5–31.
18. Hewit AT, Adler R. The retinal pigment epithelium and interphotoreceptor matrix: structure and specialized function. In: Ryan SJ, ed. *Retina*. St. Louis: CV Mosby Co.; 1989:57–64.
19. Enoch JM, Laties AM. An analysis of retinal receptor orientation. II. Predictions for psychophysical tests. *Invest Ophthalmol.* 1971;10:959–970.
20. Acharya S, Foletta VC, Lee JW, et al. SPACRCAN, a novel human interphotoreceptor matrix hyaluronan-binding proteoglycan synthesized by photoreceptors and pinealocytes. *J Biol Chem.* 2000;275:6945–6955.
21. Chen Q, Cai S, Shadrach KG, Prestwich GD, Hollyfield JG. Spacrcan binding to hyaluronan and other glycosaminoglycans. Molecular and biochemical studies. *J Biol Chem.* 2004;279:23142–23150.
22. Neveling K, Collin RW, Gilissen C, et al. Next generation genetic testing for retinitis pigmentosa. *Hum Mutat.* 2012;33:963–972.
23. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach MISCEV. Standard for full-field clinical electroretinography (2008 update). *Doc Ophthalmol.* 2009;118:69–77.
24. Spaide RF, Curcio CA. Anatomical correlates to the bands seen in the outer retina by optical coherence tomography: literature review and model. *Retina.* 2011;31:1609–1619.
25. Makiyama Y, Ooto S, Hangai M, et al. Macular cone abnormalities in retinitis pigmentosa with preserved central vision using adaptive optics scanning laser ophthalmoscopy. *PLoS One.* 2013;8:e79447.
26. Pinckers A, Cruysberg JR, van de Kerk AL. Main types of bull's eye maculopathy. Functional classification. *Doc Ophthalmol.* 1984;58:257–267.
27. Campo RV, Aaberg TM. Ocular and systemic manifestations of the Bardet-Biedl syndrome. *Am J Ophthalmol.* 1982;94:750–756.
28. Koenekoop RK, Loyer M, Hand CK, et al. Novel RPGR mutations with distinct retinitis pigmentosa phenotypes in French-Canadian families. *Am J Ophthalmol.* 2003;136:678–687.
29. Kikawa E, Nakazawa M, Chida Y, Shiono T, Tamai M. A novel mutation (Asn244Lys) in the peripherin/RDS gene causing autosomal dominant retinitis pigmentosa associated with bull's-eye maculopathy detected by nonradioisotopic SSCP. *Genomics.* 1994;20:137–139.
30. Demirci FY, Gupta N, Radak AL, et al. Histopathologic study of X-linked cone-rod dystrophy (CORDX1) caused by a mutation in the RPGR exon ORF15. *Am J Ophthalmol.* 2005;139:386–388.
31. Michaelides M, Gaillard MC, Escher P, et al. The PROM1 mutation p.R373C causes an autosomal dominant bull's eye maculopathy associated with rod, rod-cone, and macular dystrophy. *Invest Ophthalmol Vis Sci.* 2010;51:4771–4780.
32. Flynn ME, Fishman GA, Anderson RJ, Roberts DK. Retrospective longitudinal study of visual acuity change in patients with retinitis pigmentosa. *Retina.* 2001;21:639–646.
33. Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. Human photoreceptor topography. *J Comp Neurol.* 1990;292:497–523.
34. Greenstein VC, Hood DC, Ritch R, Steinberger D, Carr RE. S (blue) cone pathway vulnerability in retinitis pigmentosa, diabetes and glaucoma. *Invest Ophthalmol Vis Sci.* 1989;30:1732–1737.
35. Curcio CA. Photoreceptor topography in ageing and age-related maculopathy. *Eye (Lond).* 2001;15:376–383.
36. Curcio CA, Millican CL, Allen KA, Kalina RE. Aging of the human photoreceptor mosaic: evidence for selective vulnerability of rods in central retina. *Invest Ophthalmol Vis Sci.* 1993;34:3278–3296.
37. Okano K, Maeda A, Chen Y, et al. Retinal cone and rod photoreceptor cells exhibit differential susceptibility to light-induced damage. *J Neurochem.* 2012;121:146–156.
38. van Lith-Verhoeven JJ, Hoyng CB, van den Helm B, et al. The benign concentric annular macular dystrophy locus maps to 6p12.3-q16. *Invest Ophthalmol Vis Sci.* 2004;45:30–35.
39. Manes G, Meunier I, Avila-Fernandez A, et al. Mutations in *IMPG1* cause vitelliform macular dystrophies. *Am J Hum Genet.* 2013;93:571–578.